All Trials

A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, recurrent, or metastatic dedifferentiated liposarcoma receive oral mirdametinib (MEK1/2 inhibitor) plus palbociclib (CDK4/6 inhibitor) to evaluate safety and disease control, including patients with measurable, progressing disease and prior lines allowed (excluding prior MEK or selective CDK4 inhibitors in Phase II). Allows treated/stable brain metastases; key exclusions include significant cardiac disease/QTc >470 ms, ILD, ocular risk, strong CYP3A/UGT modulators, and inadequate organ function.

ClinicalTrials.gov ID: NCT06843967

A Phase II Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma of Soft Tissue

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults ≥65 with unresectable or metastatic soft tissue leiomyosarcoma who are anthracycline-naïve and ECOG 0–2, this single-arm study tests a lower-dose weekly doxorubicin regimen (25 mg/m2 IV on days 1 and 8 every 21 days, up to 8 cycles) with dexrazoxane and pegfilgrastim. Aims to assess 12-week PFS and tolerability, with correlative studies on immune effects of anthracycline (topoisomerase II inhibitor/DNA intercalator) therapy.

ClinicalTrials.gov ID: NCT07125183

A Phase II Study of ASTX727 in Patients With PRC2 Loss Malignant Peripheral Nerve Sheath Tumor (MPNST)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable or metastatic PRC2-loss MPNST (H3K27me2/3 loss or EED/SUZ12/EZH2 alterations) after prior therapy receive oral ASTX727 (cedazuridine/decitabine) days 1–5 of 21-day cycles with pegfilgrastim support. ASTX727 combines a cytidine deaminase inhibitor to boost exposure of decitabine, a DNA hypomethylating agent that inhibits DNMT, aiming to exploit epigenetic vulnerabilities in PRC2-deficient tumors.

ClinicalTrials.gov ID: NCT04872543

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Children and young adults (1–21 years) with relapsed/refractory GPC3-positive solid tumors (including HCC) receive cyclophosphamide/fludarabine lymphodepletion followed by a single infusion of autologous GPC3-targeted CAR T cells co-expressing IL-15 and IL-21, with an inducible caspase-9 safety switch. The investigational CAR targets the tumor proteoglycan GPC3, with IL-15/IL-21 “armoring” intended to enhance T-cell expansion and persistence.

ClinicalTrials.gov ID: NCT04715191

GALLANT: A Phase 2 Study Using Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab as Second/Third Line Therapy for Advanced Sarcoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable or metastatic sarcoma after at least one prior therapy (ECOG 0–2) receive metronomic gemcitabine, doxorubicin, and docetaxel on days 1 and 8 of 21-day cycles, with nivolumab (PD-1 inhibitor) added from cycle 2 onward, continued up to one year. Excludes patients with active autoimmune disease requiring systemic therapy or hypersensitivity to study drugs.

ClinicalTrials.gov ID: NCT04535713

A Phase I Trial of Cabozantinib (XL184) in Combination With High-dose Ifosfamide in Adults and Children With Relapsed/Refractory Ewing Sarcoma and Osteosarcoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Relapsed/refractory Ewing sarcoma (including Ewing-like) or osteosarcoma with measurable disease; enrolling children and adults (dose-finding 12–40 years; dose-confirmation 5 to <12 years) with adequate organ function and no prior high-dose ifosfamide. Treatment combines oral cabozantinib (multikinase inhibitor of MET/VEGFR2/AXL) with high-dose ifosfamide to define safety/MTD and assess preliminary activity.

ClinicalTrials.gov ID: NCT06156410

Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Maintenance cabozantinib (oral multi-kinase inhibitor of MET/VEGFR2/AXL/RET) for 12 months in children, adolescents, and young adults (≥18 months to <40 years) with ultra–high-risk solid tumors who have achieved at least stable disease after their most recent therapy and can start within 12 weeks. Includes strata such as neuroblastoma, metastatic Ewing sarcoma, osteosarcoma, high-risk rhabdomyosarcoma, DSRCT, and other high-risk sarcomas; single-arm, compared to historical controls.

ClinicalTrials.gov ID: NCT05135975

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Men with mCRPC with bone-predominant disease, asymptomatic/minimally symptomatic, castrate testosterone, prior exposure to ≤1 novel AR-targeted agent (and no visceral metastases) receive radium-223 plus Bipolar Androgen Therapy (testosterone cypionate). Radium-223 is an alpha-emitting bone-targeted radiopharmaceutical, and BAT cycles supraphysiologic testosterone to induce DNA damage and potentially re-sensitize AR signaling.

ClinicalTrials.gov ID: NCT04704505

A Phase II Randomized Study of Sipuleucel-T With or Without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer With PSA Progression While on NHA and LHRH Analog

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Asymptomatic or minimally symptomatic mCRPC patients with PSA-only progression on continuous ADT plus a new hormonal agent (abiraterone, enzalutamide, or apalutamide) and no visceral disease are randomized to receive sipuleucel‑T with the NHA continued versus stopped. Sipuleucel‑T is an autologous cellular immunotherapy activating APCs ex vivo with a PAP–GM‑CSF fusion protein; NHAs include the androgen biosynthesis inhibitor abiraterone (with prednisone) and AR signaling inhibitors enzalutamide/apalutamide.

ClinicalTrials.gov ID: NCT05751941

A Phase I, Open-label, Multi-center Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Chemo‑naïve adults with PSMA‑positive metastatic castration‑resistant prostate cancer after progression on exactly one second‑generation ARPI (ECOG 0–1, adequate renal function) receive lutetium‑177 vipivotide tetraxetan (PSMA‑targeted beta‑emitting radioligand therapy) 7.4 GBq IV every 6 weeks for up to 12 cycles with continued androgen deprivation. Prior radioligand therapy, prior mCRPC chemotherapy, significant renal impairment, and use of targeted agents (e.g., PARP inhibitors) are excluded.

ClinicalTrials.gov ID: NCT06531499